Additional Product Information Sample Clauses

Additional Product Information. If Discovery requires any existing raw or other data that verifies or supports any of the Product Information (including raw data contained in laboratory notebooks and the like) with regard to any governmental approval process or if required by any governmental approval agency, XXXX will use its best efforts to obtain such raw data from Sumitomo and/or Taisho upon Discovery's written request to XXXX. XXXX shall pay the actual cost of the translation and verification of the translation of such data. Within thirty (30) days after the receipt of a supported invoice regarding such payments, Discovery will reimburse XXXX for all such payments, provided that the translation is requested or approved by Discovery. All additional data provided to Discovery under this Section 2A(ii)(3) shall be considered Product Information hereunder.
Sample 1Sample 2
AutoNDA by SimpleDocs
Additional Product Information. The following section summarises important definitions and information relating to this product and forms part of the policy terms and conditions. Please read through this section carefully and ensure that you understand the information presented in the tables. Nominated Immediate Family Members must meet one of the following definitions and maximum age definitions as stated in the below table. Additionally, the number of lives pertaining to this category of life assureds may not exceed the stipulated number of lives in the table below. Relationship to the Main Member Definition Entry Ages (ANB) Maximum Number of lives on policy Stillborn A stillbirth is the death or loss of the Main Members baby before or during delivery At least 26 weeks *ANB is Age Next Birthday For the purpose of this policy, a marriage by common law will mean a relationship where two (2) people have been living together for at least 6 consecutive months. This is on condition that the applicant is able to provide satisfactory proof of the permanency of the relationship to Insurer. Nominated Extended Family Members must meet one of the following definitions and maximum age definitions as stated in the below table. Additionally, the number of lives pertaining to this category of life assureds may not exceed the stipulated number of lives in the table below. Relationship to the Main Member** Definition Entry Ages (ANB) Maximum Number of lives on policy* Aunt/uncle Biological siblings of the biological parents of the Main Member or Spouse. 0 – 85 8 Brother/sister Biological siblings of the Main Member or Spouse. 0 – 85 8 Son-/daughter-in- law Spouse of the Children of the Main Member. 0 – 85 8 Parent(s) Refers to the biological, adoptive or stepparents (stepfather/stepmother) of the Policyholder. 0 – 85 8 Parent(s) in law Refers to the biological, adoptive or stepparents of the Policyholders spouse. 0 – 85 8 Stepfather/- mother Spouse of the Main Member’s/Main Members spouse’ biological parent. 0 – 85 8 Stepsisters/ brothers and Children of the Spouse of the Main Member’s/Main Members spouse’ biological parent. 0 – 85 8 Grandfather/- mother Biological parent of a biological parent of the Main Member or Spouse. 0 – 85 8 Xxxxxxxx/- daughter Biological child of the Children of the Main Member. 0 – 85 8 Niece/Nephew Biological children of the biological siblings of the Main Member or Spouse 0 – 85 8 Cousin Biological children of an aunt/uncle of the Main Member or Spouse 0 – 85 8 Children mean...
Sample 1
Additional Product Information. A. ACPx. ACPx, CSG’s current product platform, will provide customers with expanded tools and capabilities (order workflow, product configurator, offer management, provisioning, trouble ticketing, and advanced Web services) to better support flexible packaging and pricing of voice, video, data, and content service bundles. Additionally, it will allow customers to more quickly and accurately bring new services (wireless, business services, advanced services, content) to market profitably. ACPx will continue to be offered via a hosted solution to our customers and leverage the ACP billing engine, as well as integrate with key CSG ancillary products like Care Express and Workforce Express.
Sample 1
Additional Product Information. Supplier will provide the following information about its Products in writing within two (2) weeks of receiving a written request from EMC: i) country of origin; ii) NAFTA preference criteria; iii) harmonized scheduled tariff classification number; and iv) export commerce control number. Upon request by EMC and subject to EMC’s reasonable assistance, Supplier will prepare all international shipping documentation, including commercial invoice, NAFTA certificate, Shipper’s Letter of Instruction, Shipper’s Export Declaration and any other necessary documentation, for international shipments.
Sample 1
Additional Product Information. (a) Attached hereto as Exhibit 2.25(a) is a product comparison showing a comparison of PMC's DurAlt FC product to existing competitive products used for the bulk treatment of gasoline. Although all the information on that Exhibit is not complete, to the best of PMC's knowledge there is no data or reasonable estimations that can be made to fill in that missing information. Other than as disclosed on Exhibit 2.25(a), to the best of PMC's knowledge, there are no products that are used in bulk treating of gasoline that provide the same or similar performance enhancing capabilities as those of DurAlt FC.
Sample 1

Related to Additional Product Information

  • Product Information EPIZYME recognizes that by reason of, inter alia, EISAI’s status as an exclusive licensee in the EISAI Territory under this Agreement, EISAI has an interest in EPIZYME’s retention in confidence of certain information of EPIZYME. Accordingly, until the end of all Royalty Term(s) in the EISAI Territory, EPIZYME shall keep confidential, and not publish or otherwise disclose, and not use for any purpose other than to fulfill EPIZYME’s obligations, or exercise EPIZYME’s rights, hereunder any EPIZYME Know-How Controlled by EPIZYME or EPIZYME Collaboration Know-How, in each case that are primarily applicable to EZH2 or EZH2 Compounds (the “Product Information”), except to the extent (a) the Product Information is in the public domain through no fault of EPIZYME, (b) such disclosure or use is expressly permitted under Section 9.3, or (c) such disclosure or use is otherwise expressly permitted by the terms and conditions of this Agreement. For purposes of Section 9.3, each Party shall be deemed to be both the Disclosing Party and the Receiving Party with respect to Product Information. For clarification, the disclosure by EPIZYME to EISAI of Product Information shall not cause such Product Information to cease to be subject to the provisions of this Section 9.2 with respect to the use and disclosure of such Confidential Information by EPIZYME. In the event this Agreement is terminated pursuant to Article 12, this Section 9.2 shall have no continuing force or effect, but the Product Information, to the extent disclosed by EPIZYME to EISAI hereunder, shall continue to be Confidential Information of EPIZYME, subject to the terms of Sections 9.1 and 9.3 for purposes of the surviving provisions of this Agreement. Each Party shall be responsible for compliance by its Affiliates, and its and its Affiliates’ respective officers, directors, employees and agents, with the provisions of Section 9.1 and this Section 9.2.

  • Additional Products Upon satisfying the minimum order requirements above, Enrolled Affiliate may order Additional Products.

  • Technical Information The Employer agrees to provide to the Union such information that is available relating to employees in the bargaining unit, as may be required by the Union for collective bargaining purposes.

  • Marketing Materials (a) During the term of this Agreement, the Sub-Adviser agrees to furnish the Manager at its principal office for prior review and approval by the Manager all written and/or printed materials, including but not limited to, PowerPointÒ or slide presentations, news releases, advertisements, brochures, fact sheets and other promotional, informational or marketing materials (the “Marketing Materials”) for internal use or public dissemination, that are produced or are for use or reference by the Sub-Adviser, its affiliates or other designees, broker-dealers or the public in connection with the Series, and Sub-Adviser shall not use any such materials if the Manager reasonably objects in writing within five business days (or such other period as may be mutually agreed) after receipt thereof. Marketing Materials may be furnished to the Manager by first class or overnight mail, facsimile transmission equipment, electronic delivery or hand delivery.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Regulatory Materials (a) Alvogen shall have the sole right to control filing or submission of Regulatory Materials with the Regulatory Agencies in the Territory with respect to Product including the MAA Approval for Product and Regulatory Approvals in the Territory, subject to Section 3.2 and the oversight of and in consultation with the Executive Steering Committee, and [***]Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. shall be responsible for managing all communications and interactions with the Regulatory Agencies in the Territory with respect to Product in the Territory. In all cases, prior to the filing of any Regulatory Materials (including the MAA for Product) for Product with the applicable Regulatory Agency, Alvogen shall provide a copy thereof to Pfenex (through the Executive Steering Committee) for its review and comment. Pfenex shall have fifteen (15) Business Days from the date it receives a copy of any Regulatory Materials with respect to the Product to provide Alvogen with comments regarding such Regulatory Materials, unless the Regulatory Agencies in the Territory or Applicable Law requires that such Regulatory Material(s) be filed on a timeline that does not reasonably permit such advanced notice, in which case Pfenex shall have as much time as is reasonably practicable to provide Alvogen with comments. Alvogen shall consider all such comments in good faith. Alvogen shall, to the extent permitted by Applicable Law, provide Pfenex with (i) reasonable advanced notice (and in no event less than fifteen (15) Business Days’ advance notice whenever feasible) of substantive meetings with any Regulatory Agency in the Territory that are either scheduled with or initiated by or on behalf of Alvogen or its Affiliates, (ii) an opportunity to have a reasonable number (but at least two (2)) representatives participate in all substantive meetings with the Regulatory Agencies in the Territory with respect to Product, and in any case keep Pfenex informed as to all material interactions with the Regulatory Agencies in the Territory with respect to Product, and (iii) a copy of any material documents, information and correspondence submitted to or received from the Regulatory Agencies in the Territory with respect to Product as soon as reasonably practicable.

  • New Products You agree to comply with NASD Notice to Members 5-26 recommending best practices for reviewing new products.

  • Research Records Each Party shall maintain records of each Research Program (or cause such records to be maintained) in sufficient detail and in good scientific manner as will properly reflect all work done and results achieved by or on behalf of such Party in the performance of such Research Program. All laboratory notebooks shall be maintained for no less than the term of any Patent issuing therefrom. All other records shall be maintained by each Party during the relevant Research Term and for [**] thereafter. All such records of a Party shall be considered such Party’s Confidential Information.

  • Promotional Materials In the event that the Fund or the Adviser makes available any promotional materials related to the Securities or the transactions contemplated hereby intended for use only by registered broker-dealers and registered representatives thereof by means of an Internet web site or similar electronic means, the Adviser will install and maintain, or will cause to be installed and maintained, pre-qualification and password-protection or similar procedures which are reasonably designed to effectively prohibit access to such promotional materials by persons other than registered broker-dealers and registered representatives thereof.

  • SALES MATERIALS 4.1 LIFE COMPANY will furnish, or will cause to be furnished, to TRUST and ADVISER, each piece of sales literature or other promotional material in which TRUST or ADVISER is named, at least ten (10) Business Days prior to its intended use. No such material will be used if TRUST or ADVISER objects to its use in writing within seven (7) Business Days after receipt of such material.

Time is Money Join Law Insider Premium to draft better contracts faster.